Pfizer to pay $55 million in drug misbranding case


WASHINGTON (AP) — The Justice Department says Pfizer Inc. will pay $55 million to resolve allegations that its subsidiary Wyeth LLC promoted the drug Protonix for uses that were not approved by the Food and Drug Administration.

In a written statement from its New York office, Pfizer, which acquired Wyeth in October 2009 years after the alleged misconduct, said that Pfizer was not a target or a subject of the case.

Wyeth obtained FDA approval to promote Protonix only for short-term treatment of erosive esophagitis. The condition is associated with gastro-esophageal reflux disease. Wyeth allegedly promoted Protonix for all forms of GERD from February 2000 to June 2001.


advertisement

GERD is a condition in which food or liquid leak backwards from the stomach into the esophagus.

Pfizer’s statement specifically denied allegations of wrongdoing.

© 2012 The Associated Press. All rights reserved.

More articles filed under Business News

Leave a Comment

Please use the comment box below for general comments, but if you feel we have made a mistake, typo, or egregious error, let us know about it. Click here to "call us out." We're happy to listen to your concerns.